Pharmacogenomics, Pharmacokinetics and Circulating Proteins As Biomarkers for Bevacizumab Treatment Optimization in Patients with Cancer: A Review

Bevacizumab is a monoclonal antibody that targets VEGF-A and inhibits tumor angiogenesis. Bevacizumab is approved for the treatment of various cancer, including metastatic colorectal cancer (mCRC), ovarian cancer, lung cancer, and others. Thus, it is widely used in oncology, but contrary to other th...

Descripción completa

Detalles Bibliográficos
Autores principales: Papachristos, Apostolos, Sivolapenko, Gregory B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563856/
https://www.ncbi.nlm.nih.gov/pubmed/32759686
http://dx.doi.org/10.3390/jpm10030079

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563856/
https://www.ncbi.nlm.nih.gov/pubmed/32759686
http://dx.doi.org/10.3390/jpm10030079

Ejemplares similares